UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 253

Sortiert nach

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

The New England journal of medicine, 2016-11, Vol.375 (18), p.1717-1725

2016

Link zum Volltext

Verfügbarkeit prüfen

Where there is inflammation, treatment may reduce disability progression – No

Multiple sclerosis, 2018-12, Vol.24 (14), p.1810-1812

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

The Lancet (British edition), 2007-08, Vol.370 (9585), p.389-397

2007

Link zum Volltext

Verfügbarkeit prüfen

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

The Lancet (British edition), 2015-09, Vol.386 (9997), p.974-981

2015

Link zum Volltext

Verfügbarkeit prüfen

Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset

NeuroImage (Orlando, Fla.), 2021-12, Vol.244, p.118589-118589, Article 118589

2021

Link zum Volltext

Verfügbarkeit prüfen

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Multiple sclerosis, 2021-10, Vol.27 (11), p.1760-1770

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

Annals of neurology, 2005-12, Vol.58 (6), p.840-846

2005

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Multiple sclerosis, 2023-05, Vol.29 (6), p.719-730

2023

Link zum Volltext

Verfügbarkeit prüfen

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Multiple sclerosis, 2022-07, Vol.28 (8), p.1277-1285

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Lancet neurology, 2009-11, Vol.8 (11), p.987-997

2009

Link zum Volltext

Verfügbarkeit prüfen

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Lancet neurology, 2011-08, Vol.10 (8), p.745-758

2011

Link zum Volltext

Verfügbarkeit prüfen

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Multiple sclerosis, 2020-07, Vol.26 (8), p.924-935

2020

Link zum Volltext

Verfügbarkeit prüfen

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

PloS one, 2015-07, Vol.10 (7), p.e0132033-e0132033

2015

Link zum Volltext

Verfügbarkeit prüfen

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Multiple sclerosis, 2021-03, Vol.27 (3), p.479-482

2021

Link zum Volltext

Verfügbarkeit prüfen

Mass Cytometry Identifies Expansion of T-bet + B Cells and CD206 + Monocytes in Early Multiple Sclerosis

Frontiers in immunology, 2021-05, Vol.12, p.653577-653577

2021

Link zum Volltext

Verfügbarkeit prüfen

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Multiple sclerosis, 2020-12, Vol.26 (14), p.1898-1906

2020

Link zum Volltext

Verfügbarkeit prüfen

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Multiple sclerosis, 2021-01, Vol.27 (1), p.90-96

2021

Link zum Volltext

Verfügbarkeit prüfen

Natalizumab in secondary progressive multiple sclerosis

Lancet neurology, 2018-05, Vol.17 (5), p.384-385

Edan, Gilles

2018

Link zum Volltext

Verfügbarkeit prüfen

Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

The New England journal of medicine, 2007-01, Vol.356 (4), p.371-378

2007

Link zum Volltext

Verfügbarkeit prüfen

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France

PloS one, 2016-12, Vol.11 (12), p.e0167556-e0167556

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Multiple sclerosis, 2019-04, Vol.25 (4), p.565-573

2019

Link zum Volltext

Verfügbarkeit prüfen

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial

Trials, 2020-06, Vol.21 (1), p.591-591, Article 591

2020

Link zum Volltext

Verfügbarkeit prüfen

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Multiple sclerosis, 2018-12, Vol.24 (14), p.1852-1861

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 253

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(228)
Mit Volltextzugriff
(233)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase

Where there is inflammation, treatment may reduce disability progression – No

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Mass Cytometry Identifies Expansion of T-bet + B Cells and CD206 + Monocytes in Early Multiple Sclerosis

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Natalizumab in secondary progressive multiple sclerosis

Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France

Focal and diffuse cervical spinal cord damage in patients with early relapsing–remitting MS: A multicentre magnetisation transfer ratio study

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Suchergebnisse filtern